Kaptchuk. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med1998; 72(3): 389–433.
2.
DevereauxPJMannsBJGhaliWA, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA2001; 285(15): 2000–2003.
3.
BeggCChoMEastwoodS, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA1996; 276(8): 637–639.
4.
SalkindNJ.Encyclopedia of research design, Vols. 1-0. Thousand Oaks, CA: SAGE, 2010.
5.
SimmonsSCohenJ.MRI findings in blinded trials should be available to treating physicians–No. Mult Scler J2021; 27(6): 814–815.
6.
VukusicSLebrun-Frenay. MRI findings in blinded trials should be available to treating physicians–Yes. Mult Scler J2021; 27(6): 812–813.
7.
University of California San Francisco MS-EPIC Team; CreeBAGourraudPA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol2016; 80(4): 499–510.
8.
StankiewiczJMWeinerHL.An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2019; 7(1): e636.
9.
SchulzKFAltmanDGMoherD.Blinding is better than masking. BMJ2007; 334(7600): 918.
